MagneMed Reports 36.71% YoY Increase in Q3 Net Profit Attributable to Shareholders; Brain-Computer Interface Business Accelerates Commercialization

China Securities News (Wang Luo) — On October 22, Medlander (688273) released its Q3 2025 earnings report and profit distribution plan for the first three quarters. According to the announcement, the company achieved revenue of 344 million yuan in the first three quarters, representing a year-on-year increase of 4.01%. The net profit attributable to shareholders was 95.9987 million yuan, with the gross margin remaining at a high level of 70.05%. The performance in Q3 was particularly outstanding, achieving a net profit attributable to shareholders of 32.0786 million yuan, marking a year-on-year growth of 36.71%, demonstrating significantly enhanced profitability momentum. Meanwhile, the company continues its stable dividend policy, proposing a dividend payout of nearly 30 million yuan.

"Serious Medical + Consumer Medical" Dual Layout Takes Shape, Brain-Computer Interface Business Accelerates Implementation

In the rehabilitation field, the company's products have covered nearly 9,000 medical institutions across China, forming a mature product matrix and sales network. In 2024, the company acquired a controlling stake in Xiaofu Technology, entering the medical aesthetics and skin management market. Its core product, the "Meiji 3D Skin Analyzer," has served over 1,200 top medical aesthetics institutions across China. The 3D modeling and AI analysis technology can seamlessly integrate with mainstream SaaS software, helping Medlander expand into new scenarios in "consumer healthcare." This marks the official formation of the company’s dual-driven industry ecosystem of "serious healthcare + consumer healthcare."

Continuous Increase in R&D Investment Provides Solid Support for Business Expansion. In the first three quarters, the company's R&D expenses increased by 12.04% year-on-year, accounting for 13.69% of its operating income. This high proportion of investment not only drives the iteration of core technologies in the rehabilitation field but also lays the foundation for breakthroughs in emerging sectors.

In emerging businesses, the implementation process in the brain-computer interface field has significantly accelerated. Since Medlander began developing its sports rehabilitation product line in 2017, it has been the first to break through the core technology of "central-peripheral synergistic closed-loop regulation." According to the company's official WeChat account, the hand function rehabilitation system has been clinically applied in over a thousand hospitals across China. In 2025, the platform construction and cooperation yielded intensive results: In May, the multi-modal brain-computer precise drive laboratory, co-built with the Ministry of Industry and Information Technology, was officially approved; in September, as one of the first member units, joined the Jiangsu Province Brain-Computer Interface Technology Innovation and Industry Service Alliance; in October, reached a strategic cooperation with Rongnao Technology for in-depth collaboration in product development, data sharing, and clinical applications.

Adhere to Twice-Yearly Dividends, Stable Returns to Shareholders

Medlander Synchronously Releases Profit Distribution Plan for the First Three Quarters of 2025, Proposing a Cash Dividend of 3 Yuan per 10 Shares to All Shareholders. Based on the total number of dividend shares as of the announcement date, 97.8079 million shares, the total proposed cash dividend amounts to 29.3424 million yuan.

This interim dividend arrangement is not the first practice; in 2024, the company has successfully implemented a "semi-annual + annual" dual dividend model, cumulatively distributing 78.6271 million yuan, with a profit distribution rate as high as 77.05% and a dividend yield exceeding 3%. This effectively shares the operating results with shareholders. A stable dividend strategy not only reflects the company's robust judgment of its operating conditions but also demonstrates its firm determination to reward shareholders over the long term, providing investors with reliable income expectations.

In the future, Medlander stated that it will continue to focus on the core track of medical rehabilitation, accelerate the clinical transformation and industrialization process of brain-computer interface technology, and promote the company's high-quality and sustainable development by relying on technological innovation and the advantages of industrial chain collaboration. Meanwhile, it will continue to share the development achievements with all shareholders through stable dividend distribution and other means.